SCHEMBL1775016

SCHEMBL1775016

O=Cc1cc(Br)c2ccccc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
CYP2A6 P11509 2/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
PLAT P00750 1/20 0.39
KLK1 P06870 1/20 0.39
KIF11 P52732 2/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 2/20 0.37
HIF1A Q16665 1/20 0.37
CYP1B1 Q16678 1/20 0.37
ERN1 O75460 2/20 0.37
CYP1A2 P05177 3/20 0.36
ALDH1A3 P47895 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP2C19 P33261 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5385215 0.78 ALDH1A1 (0.48) ALDH1A1CYP2A6KIF11NPC1RAB9A
SCHEMBL29951294 0.78 CYP1A2 (0.57) ALDH1A1CYP2A6KIF11NPC1RAB9A
SCHEMBL6362144 0.78 CYP1A2 (0.57) ALDH1A1CYP2A6KIF11NPC1RAB9A
SCHEMBL2996328 0.78 ERN1 (0.45) ALDH1A1CYP2A6KIF11NPC1RAB9A
SCHEMBL31141573 0.78 ERN1 (0.45) ALDH1A1CYP2A6KIF11NPC1RAB9A
SCHEMBL6200530 0.76 NQO2 (0.55) ALDH1A1CYP2A6RAB9AHSD17B10ERN1
SCHEMBL7841913 0.76 ALDH1A1 (0.47) ALDH1A1CYP2A6KIF11NPC1RAB9A
SCHEMBL29952947 0.76 HPRT1 (0.42) ALDH1A1CYP2A6KIF11NPC1RAB9A
SCHEMBL28139963 0.76 CYP2A6 (0.39) ALDH1A1CYP2A6KIF11NPC1RAB9A
SCHEMBL9100053 0.76 ALDH1A1 (0.45) ALDH1A1CYP2A6KIF11NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216951-B1 KRAS G12D INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-01 EP disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
EP-4216951-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2023-08-02 EP disclosed
WO-2022066646-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-03-31 WO disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
WO-2016094730-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS, INC. (US) 2016-06-16 WO disclosed
US-7943748-B2 Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-05-17 US disclosed
EP-1803721-A1 NOVEL GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-07-04 EP disclosed
CN-1989132-A Novel glucitol derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same CHUGAI PHARMACEUTICAL CO LTD (JP) 2007-06-27 CN disclosed
US-RE39590-E1 Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them ISK AMERICAS INCORPORATED (US) 2007-04-24 US disclosed
CN-1680274-A Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them ISK AMERICAS INC (US) 2005-10-12 CN disclosed
CN-1673219-A Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them ISK AMERICAS INC (US) 2005-09-28 CN disclosed
US-6545161-B2 Potato and corn crops ISK AMERICAS INCORPORATED 2003-04-08 US disclosed
US-6355799-B1 PREEMERGENT HERBICIDE FOR CEREAL CROP FIELDS, DEFOLIANT FOR POTATO AND COTTON PLANTS ISK AMERICAS INCORPORATED 2002-03-12 US disclosed
US-5155113-A Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-10-13 US disclosed
EP-0180188-B1 A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-04-15 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS FOS, FOSB, YAP1 ALDH1A1 4840/4885CYP2A6 2393/4885PLG 2565/4885
US-20230357277-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS ALDH1A1 2681/4885CYP2A6 3105/4885PLG 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.